Di Mario F, Gottardello L, Burra P, Salvagnini M, Dalrì L, Leandro G, Contento F, Torri A, Naccarato R
Divisione di Gastroenterologia R. Farini, Università e Ospedale Padova.
G Clin Med. 1990 Apr;71(4):259-62, 265-6.
Seventy-four and five cirrhotic patients with acute peptic ulcer were respectively treated with H2-blockers and cytoprotective drugs for 4-6 weeks; after this period 49 (62.2%) healed and 14 (17.7%) did not heal after further 2 months with the same therapy. In order to observe the effectiveness of H2-blockers in preventing peptic ulcer recurrences, 77 cirrhotic patients were followed-up for a mean period of 12 months (range 3-48 months) after ulcer scarring; 51.2% under H2-blockers maintenance treatment and 54.8% who took antiacid in case of need, relapsed. The therapeutical response, as regards short-term treatment in cirrhotic patients, seems not to differ from the usual outcome of the general ulcer population; on the contrary, the relapses, also during a maintenance therapy, appears increased.
74例和5例肝硬化合并急性消化性溃疡患者分别接受H2受体阻滞剂和细胞保护药物治疗4 - 6周；在此期间后，继续使用相同疗法2个月后，49例（62.2%）愈合，14例（17.7%）未愈合。为观察H2受体阻滞剂预防消化性溃疡复发的效果，77例肝硬化患者在溃疡瘢痕形成后平均随访12个月（范围3 - 48个月）；接受H2受体阻滞剂维持治疗的患者中有51.2%复发，按需服用抗酸剂的患者中有54.8%复发。关于肝硬化患者的短期治疗，其治疗反应似乎与一般溃疡人群的通常结果没有差异；相反，即使在维持治疗期间，复发率似乎也有所增加。
